Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Year: 2023
Type: supplementary-materials
Abstract: The key pharmacokinetic (PK) parameters (Supplemental Table 3) at the recommended phase 2 dose of 225 mg show that food has minimal impact on absorption of ensartinib.
Authors: Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana A. Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, Allison Holzhausen, Christine M. Lovly, Heather A. Wakelee
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361926027